Characterization of Fc receptors associated with human malignant tumors

1981 ◽  
Vol 16 (2) ◽  
pp. 179-188 ◽  
Author(s):  
Engikolai C. Krishnan ◽  
Leela Krishnan ◽  
William R. Jewell
Keyword(s):  
Malignant Tumors ◽  
Fc Receptors ◽  
Human Malignant Tumors

Variations in lymphokine generation by individual lymph nodes draining human malignant tumors

1989 ◽  
Vol 30 (5) ◽  
pp. 277-282 ◽  
Author(s):  
Duan-Ren Wen ◽  
Dave SB Hoon ◽  
Cindy Chang ◽  
Alistair J. Cochran
Keyword(s):  
Lymph Nodes ◽  
Malignant Tumors ◽  
Human Malignant Tumors

scholarly journals Molecular Determinants of Soft Tissue Sarcoma Immunity: Targets for Immune Intervention

2021 ◽  
Vol 22 (14) ◽  
pp. 7518
Author(s):  
Marcella Tazzari ◽  
Laura Bergamaschi ◽  
Alessandro De Vita ◽  
Paola Collini ◽  
Marta Barisella ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Malignant Tumors ◽  
Soft Tissue Sarcomas ◽  
Point Of View ◽  
Molecular Features ◽  
Molecular Determinants ◽  
Genetic Landscape ◽  
Current Therapies ◽  
Cumulative Evidence

Soft tissue sarcomas (STSs) are a family of rare malignant tumors encompassing more than 80 histologies. Current therapies for metastatic STS, a condition that affects roughly half of patients, have limited efficacy, making innovative therapeutic strategies urgently needed. From a molecular point of view, STSs can be classified as translocation-related and those with a heavily rearranged genotype. Although only the latter display an increased mutational burden, molecular profiles suggestive of an “immune hot” tumor microenvironment are observed across STS histologies, and response to immunotherapy has been reported in both translocation-related and genetic complex STSs. These data reinforce the notion that immunity in STSs is multifaceted and influenced by both genetic and epigenetic determinants. Cumulative evidence indicates that a fine characterization of STSs at different levels is required to identify biomarkers predictive of immunotherapy response and to discover targetable pathways to switch on the immune sensitivity of “immune cold” tumors. In this review, we will summarize recent findings on the interplay between genetic landscape, molecular profiling and immunity in STSs. Immunological and molecular features will be discussed for their prognostic value in selected STS histologies. Finally, the local and systemic immunomodulatory effects of the targeted drugs imatinib and sunitinib will be discussed.

scholarly journals The Roles of MicroRNA-141 in Human Cancers: From Diagnosis to Treatment

2016 ◽  
Vol 38 (2) ◽  
pp. 427-448 ◽  
Author(s):  
Yanping Gao ◽  
Bing Feng ◽  
Siqi Han ◽  
Kai Zhang ◽  
Jing Chen ◽  
...  
Keyword(s):  
Epithelial Mesenchymal Transition ◽  
Malignant Tumors ◽  
Untranslated Regions ◽  
Messenger Rnas ◽  
Gene Expressions ◽  
Mesenchymal Transition ◽  
Cellular Processes ◽  
Health Impairment ◽  
Non Coding Rnas ◽  
Human Malignant Tumors

Cancer remains one of the most threatening causes of human health impairment, and the mechanisms underlying tumorigenesis have not been completely characterized. MicroRNAs (miRNAs) are a group of endogenous, small (18∼25 nucleotides) non-coding RNAs which negatively regulate gene expressions by directly binding to the 3'-untranslated regions (3'-UTRs) of the target messenger RNAs (mRNAs). Increasing evidence has demonstrated abnormal miRNA profiles and confirmed their involvement in tumor initiation and progression. As one important member of the miR-200 family, microRNA (miR)-141 is aberrantly expressed in many human malignant tumors, participating in various cellular processes including epithelial-mesenchymal transition (EMT), proliferation, migration, invasion, and drug resistance. In the present review, we briefly describe the mechanisms underlying miR-141-mediated tumorigenesis and the possible future of miR-141 as a potential diagnostic and prognostic parameter as well as therapeutic target in clinical applications.

scholarly journals Gene Amplification and the Extrachromosomal Circular DNA

Genes ◽  
2021 ◽  
Vol 12 (10) ◽  
pp. 1533
Author(s):  
Noriaki Shimizu
Keyword(s):  
Gene Amplification ◽  
Malignant Tumors ◽  
Human Cancer ◽  
Replication Initiation ◽  
Matrix Attachment Region ◽  
Genome Plasticity ◽  
Sequence Element ◽  
Circular Dna ◽  
Attachment Region ◽  
Human Malignant Tumors

Oncogene amplification is closely linked to the pathogenesis of a broad spectrum of human malignant tumors. The amplified genes localize either to the extrachromosomal circular DNA, which has been referred to as cytogenetically visible double minutes (DMs), or submicroscopic episome, or to the chromosomal homogeneously staining region (HSR). The extrachromosomal circle from a chromosome arm can initiate gene amplification, resulting in the formation of DMs or HSR, if it had a sequence element required for replication initiation (the replication initiation region/matrix attachment region; the IR/MAR), under a genetic background that permits gene amplification. In this article, the nature, intracellular behavior, generation, and contribution to cancer genome plasticity of such extrachromosomal circles are summarized and discussed by reviewing recent articles on these topics. Such studies are critical in the understanding and treating human cancer, and also for the production of recombinant proteins such as biopharmaceuticals by increasing the recombinant genes in the cells.

scholarly journals Tyrosine Kinase ROR1 as a Target for Anti-Cancer Therapies

2021 ◽  
Vol 11 ◽  
Author(s):  
Yuming Zhao ◽  
Dengyang Zhang ◽  
Yao Guo ◽  
Bo Lu ◽  
Zhizhuang Joe Zhao ◽  
...  
Keyword(s):  
Tyrosine Kinase ◽  
Malignant Tumors ◽  
Wnt Signaling Pathway ◽  
Cancer Therapies ◽  
Anti Cancer ◽  
Functional Features ◽  
Survival Signaling ◽  
Preclinical And Clinical Studies ◽  
Canonical Wnt

Receptor tyrosine kinase ROR1 plays an essential role in embryogenesis and is overexpressed in many types of malignant tumors. Studies have demonstrated that it plays an important role in oncogenesis by activating cell survival signaling events, particularly the non-canonical WNT signaling pathway. Antibody-based immunotherapies targeting ROR1 have been developed and evaluated in preclinical and clinical studies with promising outcomes. However, small molecule inhibitors targeting ROR1 are underappreciated because of the initial characterization of ROR1 as a peusdokinase. The function of ROR1 as a tyrosine kinase remains poorly understood, although accumulating evidence have demonstrated its intrinsic tyrosine kinase activity. In this review, we analyzed the structural and functional features of ROR1 and discussed therapeutic strategies targeting this kinase.

scholarly journals Loss of heterozygosity (LOH) atp53 is correlated with LOH atBRCA1 andBRCA2 in various human malignant tumors

2000 ◽  
Vol 88 (2) ◽  
pp. 319-322 ◽  
Author(s):  
Dan Tong ◽  
Elisabeth Kucera ◽  
Eva Schuster ◽  
Rita K. Schmutzler ◽  
Herwig Swoboda ◽  
...  
Keyword(s):  
Loss Of Heterozygosity ◽  
Malignant Tumors ◽  
Human Malignant Tumors

The role of long non-coding RNA AFAP1-AS1 in human malignant tumors

2018 ◽  
Vol 214 (10) ◽  
pp. 1524-1531 ◽  
Author(s):  
Daolin Ji ◽  
Xiangyu Zhong ◽  
Xingming Jiang ◽  
Kaiming Leng ◽  
Yi Xu ◽  
...  
Keyword(s):  
Malignant Tumors ◽  
Non Coding Rna ◽  
Long Non Coding Rna ◽  
Human Malignant Tumors
Sign in / Sign up

Export Citation Format

Share Document